ALIMERA SCIENCES INC Form SC 13G February 09, 2017

**SECURITIES** AND **EXCHANGE** COMMISSION Washington, D.C. 20549 **SCHEDULE** 13G Under the Securities Exchange Act of 1934 (Amendment No.)\* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value \$0.01 per share (Title of Class of Securities) 016259103 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

filed:

þRule 13d-1(b) " Rule 13d-1(c) " Rule 13d-1(d)

(Page 1 of 9 Pages)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("<u>Act</u>") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

## CUSIP No. 016259103 13GPage 2 of 9 Pages

1	NAMI REPO PERS	RTING	
	venBio Select Advisor		
	LLC		
	CHEC THE	λ	
		OPRIATE	
2	BOX IF A		
	MEMBER (b) OF A		
	GROU	JP	
3	SEC USE ONLY		
		ENSHIP OR	
4	PLAC	E OF ANIZATION	
4	OKGA	ANIZATION	
	Delaw	are	
		SOLE	
	=	VOTING	
	5	POWER	
		4,034,488	
		SHARED	
NUMBER OF		VOTING	
SHARES	6	POWER	
BENEFICIALLY		0	
OWNED BY EACH		SOLE	
REPORTING		DISPOSITIVE	
PERSON WITH:	7	POWER	
		4,034,488	
		SHARED	
		DISPOSITIVE	
	8	POWER	
		0	
9	AGGI	REGATE	
	AMO		
	BENEFICIALLY		
	OWNED BY EACH		
	REPORTING		
	PERS	UN	

10	4,034,488 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
12	6.2% TYPE OF REPORTING PERSON OO, IA

## CUSIP No. 016259103 13GPage 3 of 9 Pages

	NAM	E OF	
	REPO	RTING	
1	PERS	ON	
	Behzad Aghazadeh		
	CHECK		
	THE		
	APPROPRIATE		
2	BOX	IF A	
	MEM	BER (b)	
	OF A		
	GROU	JP	
3	SEC USE ONLY		
	CITIZ	ENSHIP OR	
	PLAC	E OF	
4	ORGA	NIZATION	
	United States		
		SOLE	
		VOTING	
	5	POWER	
		4,034,488	
		SHARED	
		VOTING	
NUMBER OF	6	POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY		SOLE	
EACH		DISPOSITIVE	
REPORTING PERSON WITH:	7	POWER	
		4,034,488	
		SHARED	
		DISPOSITIVE	
	8	POWER	
		0	
9	AGGF	REGATE	
-	AMO	-	
	BENEFICIALLY		
	OWNED BY EACH		
	REPORTING		
	PERS		

	4,034,488
10	CHECK BOX
	IF THE
	AGGREGATE
	AMOUNT IN
	ROW (9)
	EXCLUDES
	CERTAIN
	SHARES
11	PERCENT OF
	CLASS
	REPRESENTED BY
	AMOUNT IN ROW
	(9)
	6.2%
	TYPE OF
	REPORTING
12	PERSON

IN

## CUSIP No. 016259103 13GPage 4 of 9 Pages

	NAM	E OF	
	REPO	RTING	
1	PERS	ON	
	Behzad Aghazadeh		
	CHECK		
	THE		
	APPROPRIATE		
2	BOX IF A		
	MEMBER (b)		
	OF A		
	GROUP		
3	SEC USE ONLY		
	CITIZ	ENSHIP OR	
	PLAC	EOF	
4	ORGA	ANIZATION	
	United States		
		SOLE	
		VOTING	
	5	POWER	
		4,034,488	
		SHARED	
		VOTING	
NUMBER OF	6	POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY		SOLE	
EACH		DISPOSITIVE	
REPORTING PERSON WITH:	7	POWER	
		4,034,488	
		SHARED	
		DISPOSITIVE	
	8	POWER	
	0	I O WER	
0	ACCT	0	
9		REGATE	
	AMOUNT		
	BENEFICIALLY		
	OWNED BY EACH REPORTING		
	PERS	UIN	

	4,034,488
10	CHECK BOX
	IF THE
	AGGREGATE
	AMOUNT IN
	ROW (9)
	EXCLUDES
	CERTAIN
	SHARES
11	PERCENT OF
	CLASS
	REPRESENTED BY
	AMOUNT IN ROW
	(9)
	6.2%
	TYPE OF
	REPORTING
12	PERSON

IN

#### CUSIP No. 016259103 13GPage 5 of 9 Pages

#### Item 1(a). NAME OF ISSUER

Alimera Sciences, Inc. (the <u>"Issuer</u>")

#### Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES

6120 Windward Parkway, Suite 290, Alpharetta, GA 30005

# Item 2(a). NAME OF PERSON FILING

This statement is filed by: (i) venBio Select Advisor LLC, a Delaware limited liability company (<u>"venBio</u>"), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of venBio Select Fund LLC, a Delaware limited liability company, and certain managed accounts and (ii) Behzad Aghazadeh (<u>"Dr. Aghazadeh</u>," and together with venBio, the <u>"Reporting Persons</u>"), who serves as the portfolio manager and controlling person of venBio.

The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

# Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE

The address of the business office of each of the Reporting Persons is 120 West 45th Street, Suite 2802, New York, NY 10036.

#### Item 2(c). CITIZENSHIP

venBio is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen.

#### Item 2(d). TITLE OF CLASS OF SECURITIES

Common Stock, par value \$0.01 per share (the "Common Stock")

#### Item 2(e). CUSIP NUMBER

016259103

### Item IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK 3. WHETHER THE PERSON FILING IS A:

- (a)" Broker or dealer registered under Section 15 of the Act;
- (b)" Bank as defined in Section 3(a)(6) of the Act;
- (c) "Insurance company as defined in Section 3(a)(19) of the Act;
- (d)" Investment company registered under Section 8 of the Investment Company Act of 1940;
- (e) þAn investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

#### CUSIP No. 016259103 13GPage 6 of 9 Pages

An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (f) "

A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (g)

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (h)"

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the (i) "Investment Company Act;

(j) "A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k)"Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution:

# Item 4. OWNERSHIP

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.

The percentage set forth in Row 11 of this Schedule 13G is calculated based upon 64,862,904 shares of Common Stock outstanding as of November 3, 2016, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2016 filed with the Securities and Exchange Commission on November 4, 2016.

#### Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable.

#### Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

See Item 2. venBio Select Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Common Stock.

#### Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

Not applicable.

### Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable.

CUSIP No. 016259103 13GPage 7 of 9 Pages

#### Item 9. NOTICE OF DISSOLUTION OF GROUP

Not applicable.

#### **Item 10. CERTIFICATION**

Each Reporting Person hereby makes the following certification:

By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 016259103 13GPage 8 of 9 Pages

#### SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATE: February 9, 2017

venBio Select Advisor LLC

/s/ Scott Epstein Name: Scott Epstein Title: Chief Financial Officer & Chief Compliance Officer

/s/ Behzad Aghazadeh BEHZAD AGHAZADEH CUSIP No. 016259103 13GPage 9 of 9 Pages

### **EXHIBIT 1**

#### JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATE: February 9, 2017

venBio Select Advisor LLC

/s/ Scott Epstein Name: Scott Epstein Title: Chief Financial Officer & Chief Compliance Officer

/s/ Behzad Aghazadeh BEHZAD AGHAZADEH